
Avastin 400mg injection
Salt Composition: Bevacizumab
Expiry Date: 01/2028
Inclusive of all taxes
1 Vial

Avastin 400mg injection
1 Vial
Bevacizumab
Salt Composition
Bevacizumab
Storage
2–8°C
Expiry Date
01/2028
Marketer
genentech
Brand
avastin

Bevatas 100mg Injection
1 Vial
Bevacizumab
Salt Composition
Bevacizumab
Storage
2–8°C
Expiry Date
01/2028
Marketer
Intas Pharmaceuticals Ltd
Brand
bevatas
5966.png&w=1920&q=75)
MAGIC DEALS
Enquire
Apply Promo Code
Available CouponsAvastin 400mg injection
Inclusive of all taxes
In Stock
Authorized
Global Reach
Verified Logistics
The price displayed is inclusive of applicable taxes. Any additional fee (such as shipping fee, handling and/or platform fee etc.) will be clearly disclosed before you complete your purchase.
About The Product
Avastin 400mg injection belongs to the category of anticancer medicines. This medicine is primarily used to treat patients diagnosed with brain cancer, cervical cancer, kidney cancer, lung cancer, ovarian cancer, and colorectal cancer. The growth of cancer cells is uncontrollable and abnormal in the human body. It is difficult to diagnose cancer in the early stages.
When diagnosed in advanced stages, only the symptoms of the disease can be reduced. Avastin injection is typically administered in combination with another anticancer medication as part of a combination therapy to enhance the treatment's efficacy. It is given as an infusion, which means it is given into the veins through a small needle or port (device placed under your skin).
Overview
Avastin 400mg/16mL injection contains bevacizumab, a recombinant humanized anti-VEGF (vascular endothelial growth factor) monoclonal antibody manufactured by Roche/Genentech. Avastin 400mg/16mL injection was the first anti-angiogenic oncology therapy approved (2004 for colorectal cancer) and remains one of the most widely used cancer biologics globally.
It works by binding VEGF-A and blocking tumor angiogenesis—cutting off the blood supply that tumors need to grow and spread. Avastin 400mg/16mL injection is approved for 8+ tumor types.
Critical combination: Atezo+Bev (Tecentriq+Avastin) is the standard first-line therapy for advanced HCC. Avastin 400mg/16mL injection is administered with chemotherapy across multiple indications and is not active as a single agent.
Patients and caregivers in India can find information about Avastin 400mg/16mL injection availability, prescription verification, and treatment access support.
Quick Product Facts
Brand Name | Avastin |
Generic Name | Bevacizumab |
Drug Class | Anti-VEGF Monoclonal Antibody — Recombinant Humanised IgG1 |
Manufacturer | Roche / Genentech |
Dose | 5mg/kg or 10mg/kg or 15mg/kg Q2W or Q3W — indication-dependent |
Route | IV infusion — 90 min (first); 60 min (second); 30 min (subsequent) |
Key Combination | Atezo+Bev for HCC | + Chemo for CRC, NSCLC, Ovarian, Cervical |
Storage | Refrigerate 2°C–8°C. Protect from light. Do NOT freeze. |
Prescription | Yes — Oncologist mandatory |
Uses and Indications
Colorectal Cancer (CRC) — First and Second-Line
Avastin 400mg/16mL + FOLFOX/FOLFIRI/XELOX for metastatic CRC. First-line: 5mg/kg Q2W or 7.5mg/kg Q3W. Second-line: 5mg/kg Q2W with FOLFIRI after first-line oxaliplatin-based failure. Established survival benefit in multiple CRC trials (AVF2107, E3200).
Non-Small Cell Lung Cancer (NSCLC) — Non-Squamous
Avastin 15mg/kg + Carboplatin + Paclitaxel Q3W for advanced non-squamous NSCLC. Also Atezolizumab + Bev + Carbo + Paclitaxel (ABCP regimen—IMpower150). NOT for squamous histology (haemorrhage risk).
Ovarian Cancer
First-line: Avastin 400mg/16mL + Carboplatin + Paclitaxel for Stage III/IV ovarian cancer; maintenance 15mg/kg Q3W for 12-22 cycles (ICON7/GOG-0218). Also platinum-resistant recurrence.
Hepatocellular Carcinoma (HCC)—Atezo+Bev
Atezolizumab 1200mg + Avastin 15mg/kg IV Q3W for unresectable HCC (IMbrave150). Now the global standard of care is first-line. Variceal screening is mandatory before starting.
Other Indications
Cervical cancer (+ platinum + paclitaxel ± topotecan), glioblastoma (after progression), Renal cell carcinoma.
How It Works
An anti-angiogenic medication, Avastin 400mg injection, works by blocking vascular endothelial growth factor (VEGF), which is a protein.
It basically functions by cutting the oxygen supply and nutrients to cancerous cells by stopping the formation of blood vessels that supply them.
Clinical Evidence
IMbrave150 (HCC — Atezo+Bev)
Atezo 1200mg + Bev 15mg/kg vs Sorafenib Q3W for first-line unresectable HCC. OS: 19.2 vs 13.4 months. PFS: 6.8 vs 4.3 months. ORR 27.3% vs 11.9%. Changed global HCC treatment standard.
GOG-0218 (Ovarian Cancer)
Avastin 400mg/16mL + Carboplatin + Paclitaxel → Avastin 400mg/16mL Injection maintenance for Stage III/IV ovarian cancer. PFS: 14.1 vs 10.3 months for maintenance arm. OS benefit in high-risk subgroups. Established Avastin 400mg/16mL Injection in front-line ovarian cancer.
AVF2107 (Metastatic CRC — First-Line)
Avastin 400mg/16mL + IFL chemotherapy vs IFL alone for first-line mCRC. OS: 20.3 vs 15.6 months. ORR 44.8% vs 34.8%. First clinical proof of anti-angiogenic benefit in CRC — landmark 2004 approval trial.
KEYNOTE-826 (Cervical Cancer — Pembrolizumab ± Bev)
Pembrolizumab + Chemo ± Avastin for metastatic cervical cancer. The Avastin 400mg/16mL Injection arm added further PFS and OS benefit on top of immunotherapy + chemotherapy.
Side Effects
The human body shows undesired symptoms after taking the Avastin 400mg injection. Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention. It is advised to consult your doctor if these symptoms become unmanageable. Some of the side effects of Avastin injection are mentioned below:
Common side effects
Fever
Fatigue
Back pain
Headache
Mouth sore
Weight loss
Constipation
Nose bleeding
Breathlessness
Taste alteration of appetite
Abdominal pain, increased heart rate
High blood pressure
Nausea and vomiting
Numbness in hands and feet.
Severe side effects
Gut infection
Blood clotting
Hemorrhage
Protein in urine
Decrease in the level of white blood cells
Critical Safety Warning
⚠ GI PERFORATION, HAEMORRHAGE, AND WOUND HEALING — CRITICAL RISKS
Avastin 400mg/16mL Injection carries three serious surgical and vascular risks: (1) GI perforation—can be life-threatening; stop immediately if suspected. (2) Serious hemorrhage—including pulmonary hemorrhage in NSCLC (not indicated in squamous histology) and CNS hemorrhage in brain metastases. (3) Wound healing impairment—do not administer within 28 days before or after surgery; do not restart until wound fully healed. Additionally: hypertension must be controlled before starting and monitored throughout. Proteinuria requires dose interruption if ≥2g/24h and permanent discontinuation for nephrotic syndrome.
⚠ INDICATION IN SQUAMOUS NSCLC
Avastin 400mg/16mL Injection is not indicated for squamous cell non-small cell lung cancer (NSCLC) due to significantly increased risk of life-threatening or fatal pulmonary hemorrhage (up to 31% in initial trials). Always confirm NSCLC histology before prescribing Avastin 400mg/16mL Injection.
Dosage and How To Take It
Avastin 400mg/16mL injection is administered by IV infusion. Do not give as IV bolus or push.
First infusion: 90 minutes. If tolerated: second infusion in 60 minutes. Subsequent infusions: 30 minutes if well tolerated.
Colorectal cancer (first-line): 5mg/kg IV Q2W or 7.5mg/kg IV Q3W.
NSCLC: 15mg/kg IV Q3W with chemotherapy (non-squamous ONLY).
Ovarian cancer: 15mg/kg IV Q3W with chemotherapy, then maintenance.
HCC (Atezo+Bev): 15mg/kg IV Q3W with Atezolizumab 1200mg.
Cervical cancer: 15mg/kg IV Q3W with chemotherapy.
No dose reductions—modify by interruption or discontinuation based on toxicity.
The availability of Avastin 400mg/16mL injection in India is dependent on the stock as well as the cold-chain supply logistics. Both patients and caregivers may inquire regarding the availability, pan-India delivery, prescription verification, as well as the treatment access support related to Avastin 400mg/16mL Injection. |
Missed Doses
- It is advised not to miss any scheduled dosage of Avastin 400mg injection.
- In case you miss a dose, consult your doctor immediately.
- Don't overdose to compensate for the missed one.
- Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.
Safety Advice
The interaction of alcohol with this drug is still unknown. It is advisable not to consume alcohol while taking Avastin 400mg injection. It is advised to consult your doctor for further information.
Avastin 400mg injection may be considered unsafe during pregnancy. Please consult your doctor in such condition.
It is advisable not to drive or operate heavy machinery as you may feel dizzy after taking Avastin 400mg injection.
Share your medical history with your healthcare expert in case of kidney disease before taking Avastin 400mg injection.
Inform your doctor before starting Avastin 400mg injection if you have liver disease to avoid any serious side effects.
Monitoring During Treatment
The following parameters must be monitored throughout treatment:
Parameter | Frequency | Action if Abnormal |
Blood pressure | Each cycle, plus home monitoring | Antihypertensives for sustained elevation; hold for hypertensive crisis |
Urine protein (dipstick → 24h if positive) | Each cycle | Hold for ≥2g/24h proteinuria; discontinue for nephrotic syndrome |
Wound inspection | Before each infusion | Do not give if wound not fully healed; document healing status post-surgery |
Liver function (HCC patients) | Q3W | Monitor hepatic reserve — Child-Pugh score relevant to Bev tolerability |
Variceal assessment (HCC) | Before starting Atezo+Bev | Upper GI endoscopy; treat varices before starting Avastin 400mg/16mL Injection — haemorrhage risk |
CBC | Each cycle (with chemo regimens) | Standard myelosuppression monitoring with combination chemotherapy |
Fact Box
Parameter | Details |
Brand Name | Avastin |
Generic Name | Bevacizumab |
Manufacturer | Roche / Genentech |
First Approval | 2004 — first anti-angiogenic therapy approved in oncology |
Drug Class | Anti-VEGF Monoclonal Antibody — Recombinant Humanised IgG1 (rhuMAb VEGF) |
Target | VEGF-A (Vascular Endothelial Growth Factor A) |
Mechanism | Binds VEGF-A → blocks tumour angiogenesis → impairs tumour blood supply |
Active as Monotherapy | No — must be combined with chemotherapy or immunotherapy |
Standard Doses | 5-15mg/kg Q2W or Q3W — indication-dependent |
Critical Contraindication | Squamous NSCLC — pulmonary haemorrhage risk |
Storage | Refrigerate 2°C–8°C. Protect from light. Do NOT freeze. |
Prescription | Yes — Oncologist mandatory |
Habit Forming | No |
Drug Interactions
Drug / Class | Potential Interaction or Risk | What To Do |
Platinum-based chemotherapy (Carboplatin, Cisplatin) | Increased renal toxicity risk. | Ensure adequate hydration and monitor renal function. |
Taxanes (Paclitaxel, Docetaxel, Nab-paclitaxel) | Increased peripheral neuropathy risk. | Monitor for neuropathy throughout treatment. |
Atezolizumab (Atezo + Bev) | Increased risk of hepatotoxicity and immune-related adverse events. | Monitor LFTs and immune-related toxicities regularly. |
Anticoagulants (Warfarin, DOACs, LMWH) | Increased bleeding risk. | Monitor for bleeding and INR with warfarin. |
Sunitinib | Risk of microangiopathic haemolytic anaemia (MAHA) and thrombotic microangiopathy. | Avoid concurrent use. |
Surgery / wound management | Impaired wound healing due to VEGF inhibition. | Withhold for at least 28 days before and after major surgery, until adequate wound healing. |
Always inform your treating oncologist about ALL medications, herbal supplements, and immunosuppressants before starting treatment. |
FAQs
Avastin injection can pass through the mother's blood and harm the unborn baby.
So, it is advised not to give this drug to pregnant and breastfeeding women.
Reference
Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. (2023). Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 114(5):855-9
Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. (2024). Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 114(12):2179-82
Oguchi Y, Sekiryu T, Omori T, Kato Y, Ogasawara M, Sugano Y, Itagaki K, Ojima A, Machida T, Sekine H. (2025). Anaphylatoxin concentration in aqueous and vitreous humor in the eyes with vitreoretinal interface abnormalities. Exp Eye Res;195:108025
Emerson MV, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT, Emerson GG, Schlesinger TK, Nolte SK, Klein ML. (2023). Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 27(4):439-44
Kumar A, Sinha S. (2025). Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Indian J Ophthalmol. 55(6):451-5
Kandasamy R, Constantinou M, Rogers SL, Sandhu SS, Wickremasinghe S, Al-Qureshi S, Lim LL. (2024). Prospective randomised clinical trial of intravitreal bevacizumab versus triamcinolone in eyes with diabetic macular oedema undergoing cataract surgery: 6-month results. Br J Ophthalmol. 103(12):1753-1758.
Taira K, Okazaki S, Akiyoshi K, Machida H, Ikeya T, Kimura A, Nakata A, Nadatani Y, Ohminami M, Fukunaga S, Otani K, Hosomi S, Tanaka F, Kamata N, Nagami Y, Fujiwara Y. (2023). Short bevacizumab infusion is an effective and safe treatment for colorectal cancer. Mol Clin Oncol. 17(3):139.
Perdrizet K, Leighl NB. (2024). The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer. Curr Treat Options Oncol. 18;20(3):21
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.jpeg%3FupdatedAt%3D1763121181831&w=128&q=75)